Nauge Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.79 M
- Company Age 35 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
- Revenue Growth 1.93%
- Profit Growth -29.67%
- Ebitda -21.70%
- Net Worth -15.46%
- Total Assets -8.93%
About Nauge Pharmaceuticals
Nauge Pharmaceuticals Pvt Ltd (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 February 1989 and has a history of 35 years and 11 months. Its registered office is in Medak, Telangana, India.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.79 M.
The company currently has active open charges totaling ₹5.00 Cr.
Priyanandana Mudunuri, Sailaja Rudraraju, and Venkata Kanumuru serve as directors at the Company.
Company Details
-
Location
Medak, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230TG1989PTC009568
-
Company No.
009568
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Feb 1989
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Nauge Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyanandana Mudunuri
|
Director | 16-Oct-2023 | Current |
|
Sailaja Rudraraju
|
Director | 29-Oct-2002 | Current |
|
Venkata Kanumuru
|
Director | 29-Oct-2002 | Current |
Financial Performance of Nauge Pharmaceuticals.
Nauge Pharmaceuticals Pvt Ltd, for the financial year ended 2021, experienced modest growth in revenue, with a 1.93% increase. The company also saw a substantial fall in profitability, with a 29.67% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nauge Pharmaceuticals?
In 2021, Nauge Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹50.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 5.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Jul 2003 | State Bank Of India | ₹5.00 Cr | Open |
How Many Employees Work at Nauge Pharmaceuticals?
Unlock and access historical data on people associated with Nauge Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nauge Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nauge Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
